Impact of HCV infection in a HIV cohort followed over18 years: past and present by Mena, Álvaro et al.
Impact of HCV infection in a HIV cohort followed over18 years: 
past and present 
A. Mena
1
, I. Rodríguez Osorio
1
, H. Meijide
1
, Á. Castro Iglesias
1
, S. López Calvo
1
, P. 
Vázquez Rodríguez
1
, B. Pernas
1
, M. Grandal
1
, J. Domingo Pedreira
1
, E.Poveda
1
. 
1 Division of Clinical Virology, INIBIC-CHUAC, A Coruña, Spain 
Background and Aims: This study evaluates the impact of HCV infection in a cohort of HIV infected 
patients followed over 16years and trends in hospitalizations and mortality. 
 
Methods: A cohort of HIV-infected patients was followed at our institution between 1996–2013. 
Epidemiological, clinical and main data related with hospitalizations and mortality was recorded. Data 
has been analyzed considering HIV-mono and HIV/HCV populations and two periods of nine years each. 
 
Results: A total of 2257 HIV infected patients (857 HIV/HCV co-infected) were retrospectively 
examined over 16 years. Overall, 76%were men, median age of 31 (25–37) years and 57% have an AIDS 
event during the follow-up. Patients under antiretroviral therapy (ART) was similar in HIV/HCV and 
HIV-mono in both periods (>87%).Main results are depicted in the table 
Variable 1996–2004    2005–2013   
 HIV HIV/HCV p  HIV HIV/HCV p 
        
N patients (%) 905 (55) 730 (45)   997 (59) 694 (41)  
Follow-up (years) 6.8±4.7 9.4±4.8 0.001  11.6±4.3 16.4±4.8 0.001 
Mortality (%) 311 (34) 275 (37) 0.085  178 (18) 189 (27) <0.001 
Infectious (%) 172 (55) 102 (37) 0.040  60 (34) 41 (22) 0.035 
Tumoral (%) 62 (20) 27 (10) 0.020  56 (31) 34 (18) 0.020 
Cardiovascular (%) 17 (5) 8 (3) 0.045  23 (13) 18 (9) 0.080 
Liver-related mortality (%) 7 (2) 74 (27) <0.001  1 (1) 72 (38) <0.001 
Hospitalizations 1899 1398 0.110  1297 1458 0.050 
Infectious (%) 845 (44) 544 (39) 0.060  454 (35) 517 (35) 0.220 
Liver-related (%) 59 (3) 119 (8) 0.001  46 (3) 183 (13) <0.001 
        
 
Overall, HIV/HCV co-infected population have significant lower CD4counts (cell/mm3) in both periods 
(505 vs 312 and 542 vs 322;p<0.001, respectively). A lower rate of patients achieved HIV-RNA<50 
cop/mL in the second period compared with HIV-mono (59.2 vs56.4 and 75.3 vs 67.2; p=0.03, 
respectively). In this population, a low rate of patients received HCV treatment although was higher in the 
second period (6.9% vs 11.5%, p=0.01). Consequently, a higher proportion of patients achieved sustained 
virological response (SVR)in the second period (61% vs 70%, p=0.03). The rate of liver-related mortality 
was significantly higher in HIV/HCV compared with HIV-monoinfected with an increase in the second 
period (p=0.02). Moreover, hospitalizations related with liver-disease were higher in HIV/HCV and were 
higher in the second period (p=0.04).Among patients achieving SVR, only 3.2% and 3.6% in both 
periods, respectively, had a liver-related hospitalization and none died. 
  
Conclusions: HCV infection has a negative impact on HIV outcome related with lower CD4 recovery 
and lower rates of virological success in HIV/HCV patients under ART. However, HCV infection does 
not impact on the mortality related with infectious, tumoral or cardiovascular diseases and only increase 
the rate of liver-related mortality in HIV/HCV patients compared with HIV-monoinfected. Moreover, 
HCV infection significantly increased liver-related hospitalizations and mortality on the long-term. 
Considering the low rate of patients receiving HCV treatment in this cohort, these data confirm the 
harmful contribution of uncontrolled HCV infection in HIV/HCV infected population. 
 
 
